Anti-Glucagon Antibody (8)
Our mouse Glucagon monoclonal antibody from Antibodies Incorporated is produced in-house from clone 8. It detects human, pig, and rat Glucagon and is Protein A or Protein G purified. Works in ELISA.
SKU: ABS 058-08-010
Ships: 1-2 business days
Product Details
Glucagon
Glucagon is a peptide hormone of 29 amino-acid residues produced by the alpha cells of the pancreatic islets. Its effect is to raise blood sugar as a stress hormone and counter-regulatory hormone for insulin. It is produced by cell-type-specific processing of proglucagon, which in the alpha cells is split to form glicentin-related pancreatic polypeptide, glucagon and major proglucagon fragment, while the same precursor is split to form glicentin, oxyntomodulin (C-terminally extended glucagon-37), GLP-1 and GLP-2 in the L cells of the intestinal mucosa.
Protein A or Protein G purified
1 mg/mL ±15%
Monoclonal
8
IgG1/k
ELISA
Mouse
GCG
20.4 kDa
Synthetic N-terminal fragment of glucagon coupled to carrier
Human
Human
2-8°C without exposure to light
Liquid
BSA free
0.01 M phosphate buffer, pH 7.4, with 0.5 M NaCl and 15 mM sodium azide
ABS 058-08 binds free glucagon in solution. ABS 058-08 (as biotinylated detection antibody) forms a sandwich ELISA pair with ABS 061-09 (as capture antibody) for measuring glucagon.
Unconjugated
ABS 058-08 binds human glucagon. The epitope lies within the N-terminal half of human glucagon
These antibodies are to be used as research laboratory reagents and are not for use as diagnostic or therapeutic reagents in humans.
United States
24 months from date of receipt
GCG; Pro-glucagon; Cleaved into: Glicentin; Glicentin-related polypeptide; GRPP; Oxyntomodulin; OXM; OXY; Glucagon; Glucagon-like peptide 1; GLP-1; Incretin hormone; Glucagon-like peptide 1(7-37; GLP-1(7-37; Glucagon-like peptide 1(7-36; GLP-1(7-36; Glucagon-like peptide 2; GLP-2; GLP1; GLP2; incretin; preproglucagon
P01275
UniProt Summary: [Glucagon]: Plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes. Binds to and activates the glucagon receptor GCGR, which couples to the G(s) G protein and elevates intracellular cAMP, triggering downstream metabolic responses (PubMed:32193322). {ECO:0000269|PubMed:32193322, ECO:0000303|PubMed:10605628, ECO:0000303|PubMed:12626323}.; [Glucagon-like peptide 1]: Potent stimulator of glucose-dependent insulin release (PubMed:22037645, PubMed:40446798). Also stimulates insulin release in response to IL6 (PubMed:22037645). Plays important roles on gastric motility and the suppression of plasma glucagon levels (PubMed:10605628, PubMed:14719035, PubMed:12554744). May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin (PubMed:10605628, PubMed:14719035, PubMed:12554744). Has growth-promoting activities on intestinal epithelium (PubMed:10605628, PubMed:14719035, PubMed:12554744). May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion (PubMed:10605628, PubMed:14719035, PubMed:12554744). Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferation (PubMed:10605628, PubMed:14719035, PubMed:12554744). Inhibits beta cell apoptosis (PubMed:10605628, PubMed:14719035, PubMed:12554744). {ECO:0000269|PubMed:22037645, ECO:0000269|PubMed:40446798, ECO:0000303|PubMed:10605628, ECO:0000303|PubMed:12554744, ECO:0000303|PubMed:14719035}.; [Glucagon-like peptide 2]: Stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability. {ECO:0000303|PubMed:10322410, ECO:0000303|PubMed:10605628, ECO:0000303|PubMed:12554744, ECO:0000303|PubMed:14719035}.; [Oxyntomodulin]: Significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness. {ECO:0000303|PubMed:10605628, ECO:0000303|PubMed:12554744}.; [Glicentin]: May modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life. {ECO:0000303|PubMed:10605628, ECO:0000303|PubMed:12554744}.
UniProt Summary: [Glucagon]: Plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes. Binds to and activates the glucagon receptor GCGR, which couples to the G(s) G protein and elevates intracellular cAMP, triggering downstream metabolic responses (PubMed:32193322). {ECO:0000269|PubMed:32193322, ECO:0000303|PubMed:10605628, ECO:0000303|PubMed:12626323}.; [Glucagon-like peptide 1]: Potent stimulator of glucose-dependent insulin release (PubMed:22037645, PubMed:40446798). Also stimulates insulin release in response to IL6 (PubMed:22037645). Plays important roles on gastric motility and the suppression of plasma glucagon levels (PubMed:10605628, PubMed:14719035, PubMed:12554744). May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin (PubMed:10605628, PubMed:14719035, PubMed:12554744). Has growth-promoting activities on intestinal epithelium (PubMed:10605628, PubMed:14719035, PubMed:12554744). May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion (PubMed:10605628, PubMed:14719035, PubMed:12554744). Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferation (PubMed:10605628, PubMed:14719035, PubMed:12554744). Inhibits beta cell apoptosis (PubMed:10605628, PubMed:14719035, PubMed:12554744). {ECO:0000269|PubMed:22037645, ECO:0000269|PubMed:40446798, ECO:0000303|PubMed:10605628, ECO:0000303|PubMed:12554744, ECO:0000303|PubMed:14719035}.; [Glucagon-like peptide 2]: Stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability. {ECO:0000303|PubMed:10322410, ECO:0000303|PubMed:10605628, ECO:0000303|PubMed:12554744, ECO:0000303|PubMed:14719035}.; [Oxyntomodulin]: Significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness. {ECO:0000303|PubMed:10605628, ECO:0000303|PubMed:12554744}.; [Glicentin]: May modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life. {ECO:0000303|PubMed:10605628, ECO:0000303|PubMed:12554744}.
2641
Shipped on ice packs

